| Literature DB >> 33369464 |
Toru Miyazaki1, Hiroji Shinkawa1, Shigekazu Takemura1, Shogo Tanaka1, Ryosuke Amano1, Kenjiro Kimura1, Go Ohira1, Kohei Nishio1, Masahiko Kinoshita1, Jun Tsuchi1, Atsushi Ishihara1, Shimpei Eguchi1, Daisuke Shirai1, Takatsugu Yamamoto2, Kenichi Wakasa3, Norifumi Kawada4, Shoji Kubo1.
Abstract
BACKGROUND: Cholangiocarcinoma and secondary biliary cirrhosis can develop after liver resection for hepatolithiasis and are causes of hepatolithiasis-related death. We determined potential risk factors for hepatolithiasis-related death and subsequent cholangiocarcinoma, including precancerous lesions such as biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm of the bile duct, in patients undergoing liver resection for hepatolithiasis.Entities:
Keywords: Biliary intraepithelial neoplasia; biliary cirrhosis; cholangiocarcinoma; hepatolithiasis; liver atrophy
Year: 2020 PMID: 33369464 PMCID: PMC8046297 DOI: 10.31557/APJCP.2020.21.12.3647
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Characteristics of Five Patients with Subsequent Cholangiocarcinoma
| First operation | Cholangiocarcinoma | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient No. | Age | Sex | Operative | Liver atrophy | Residual stones | BilIN or IPNB | Expression of γ-H2AX | Expression of S100P | Duration between first surgery and cholangiocarcinoma diagnosis | Site | Stage | Treatments | Duration between diagnosis of cholangiocarcinoma and mortality |
| 1 | 48 | M | Right posterior sectionectomy and Segmentectomy 3 | Positive | Negative | low-grade BilIN | Positive | Positive | 18 years | Right hepatic duct - extrahepatic bile duct | IIIA | Radiation | 1 year |
| 2 | 45 | M | Right hepatectomy and Segmentectomy 3 | Positive | Positive | low-grade BilIN | Positive | Positive | 2 years 3 months | Left hepatic duct - medial segment, bone metastasis | IVB | Conservative | 7 months |
| 3 | 57 | F | Left hepatectomy with segmentectomy 1 | Positive | Negative | low-grade IPNB | NA‡ | NA‡ | 17 years | Extrahepatic bile duct | II | Resection of extrahepatic bile duct and hepaticojejunostomy, adjuvant chemotherapy | 7 years† |
| 4 | 58 | M | Left hepatectomy with segmentectomy 1 | Positive | Negative | low-grade BilIN | Positive | Positive | 10 years | Extrahepatic bile duct | IVA | Conservative | 4 months |
| 5 | 82 | F | Left lateral sectionectomy | Positive | Negative | high-grade BilIN | Positive | Positive | 3 years 9 months | Left hepatic duct - medial segment | IVA | Segmentectomy 4 | 3 months |
BilIN, biliary intraepithelial neoplasia; IPNB, intraductal papillary neoplasm of the bile duct; M, male; F, Female; †, The chemotherapy was performed for the recurrence of cholangiocarcinoma that was detected at 5 years and 7 months after the operation for subsequent cholangiocarcinoma; ‡, The surgical specimens were not available.
Figure 1Representative Computed Tomography Images, Surgical Specimens, and Pathological Findings of One Patient (Patient No. 5) with Subsequent Cholangiocarcinoma after Liver Resection for Hepatolithiasis. (A) Computed tomography image before the first surgery shows intrahepatic stones, bile duct dilation, and liver atrophy. (B) Prominent bile duct dilation and liver atrophy are observed in macroscopic examination of the specimen resected in the first operation. (C) Low-grade biliary intraepithelial neoplasia (BilIN) is observed in the surgical specimen of the first operation. Hematoxylin and eosin (HE) staining. Magnification, ×400. (D) High-grade BilIN is observed in a surgical specimen of the first operation. HE staining. Magnification, ×400. (E) Computed tomography image before the second surgery shows cholangiocarcinoma (arrow) adjacent to the stump of the resected bile duct (the branching point of the bile duct of the medial segment and left hepatic duct). The dilatation of the intrahepatic bile ducts in the right lobe (arrow head) were also observed. (F) Bile duct dilation and cholangiocarcinoma (arrow) are observed in macroscopic examination of the specimen resected in the second operation. (G) High-grade BilIN is observed in the surgical specimen resected in the second operation. HE staining. Magnification, ×200. (H) Cholangiocarcinoma (well-differentiated adenocarcinoma) in the surgical specimen resected in the second operation
Univariate Analysis of Risk Factors for Hepatolithiasis-Related Death Using the Log-Rank Test
| Variables | Number | Survival rate (%) | P value | ||
|---|---|---|---|---|---|
| 3 years | 7 years | 10 years | |||
| Age, years | |||||
| <65 | 43 | 98 | 94 | 91 | 0.627 |
| ≥65 | 19 | 100 | 94 | 84 | |
| Sex | |||||
| Male | 22 | 95 | 88 | 81 | 0.164 |
| Female | 40 | 100 | 97 | 97 | |
| Period from onset to surgery (years) | |||||
| <10 | 36 | 100 | 92 | 86 | 0.576 |
| ≥10 | 26 | 96 | 96 | 92 | |
| History of cholecystectomy | |||||
| Present | 21 | 100 | 100 | 100 | 0.0974 |
| Absent | 41 | 97 | 95 | 84 | |
| History of choledocho-enterostomy | |||||
| Present | 3 | 100 | 100 | 100 | 0.694 |
| Absent | 59 | 98 | 96 | 89 | |
| CA19-9 (U/mL) | |||||
| <37 | 34 | 100 | 97 | 86 | 0.97 |
| ≥37 | 7 | 86 | 86 | 86 | |
| Preoperative cholangitis | |||||
| Present | 3 | 100 | 100 | 100 | 0.714 |
| Absent | 42 | 97 | 95 | 87 | |
| Bile duct stenosis | |||||
| Present | 51 | 98 | 96 | 88 | 0.289 |
| Absent | 11 | 100 | 100 | 100 | |
| Biliary reconstruction | |||||
| Present | 10 | 100 | 100 | 83 | 0.454 |
| Absent | 52 | 98 | 93 | 90 | |
| Liver atrophy of affected segment (s) | |||||
| Present | 16 | 94 | 87 | 70 | 0.000599 |
| Absent | 46 | 100 | 97 | 97 | |
| Precancerous lesions † | |||||
| Present | 29 | 96 | 88 | 77 | 0.0149 |
| Absent | 33 | 100 | 100 | 100 | |
| Residual stones after surgery | |||||
| Present | 8 | 88 | 88 | 88 | 0.49 |
| Absent | 54 | 98 | 95 | 89 | |
| Stone recurrence | |||||
| Present | 5 | 100 | 75 | 50 | 0.162 |
| Absent | 56 | 98 | 96 | 93 | |
| Postoperative repeated cholangitis | |||||
| Present | 13 | 100 | 89 | 78 | 0.00942 |
| Absent | 49 | 98 | 95 | 92 | |
| Postoperative jaundice | |||||
| Present | 14 | 100 | 80 | 80 | 0.00831 |
| Absent | 48 | 98 | 95 | 91 | |
†, Precancerous lesions include biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct; CA19-9, carbohydrate antigen 19-9
Figure 2Hepatolithiasis-Related Death-Free Survival Rates in Patients with and without Precancerous Lesions
Characteristics of Patients with and without Subsequent Cholangiocarcinoma
| Hepatolithiasis without subsequent cholangiocarcinoma | Hepatolithiasis with subsequent cholangiocarcinoma | P value | |
|---|---|---|---|
| Age > 65 years | 18/57 | 1/5 | 0.999 |
| Sex (M/F) | 19:38 | 3:02 | 0.337 |
| Period from onset to surgery (>10 years) | 23/57 | 3 | 0.641 |
| History of cholecystectomy | 21/57 | 0/5 | 0.157 |
| History of choledocho-enterostomy | 3/57 | 0/5 | >0.999 |
| Tumor marker levels immediately before surgery | |||
| CEA > 5.0 ng/mL | 0/51 † | 0/5 | |
| CA19-9 > 37 U/mL | 6/36 † | 1/5 | >0.999 |
| Preoperative cholangitis | 37/40 † | 5/5 | >0.999 |
| Location of stones | 0.667 | ||
| Right | 10 | 0 | |
| Left | 34 | 3 | |
| Both | 13 | 2 | |
| Bile duct stenosis | 46/57 | 5/5 | 0.575 |
| Bile duct dilatation | 31/57 | 3/5 | >0.999 |
| Operative procedure | 0.651 | ||
| Right hepatectomy ‡ | 5 | 1 | |
| Left hepatectomy ‡ | 18 | 2 | |
| Left lateral sectionectomy | 23 | 1 | |
| Other type resections | 11 | 1 | |
| Biliary reconstruction | 9/57 | 1/5 | >0.999 |
| Liver atrophy of affected segment(s) | 12/57 | 4/5 | 0.0136 |
| Precancerous lesions ‡† | 24/57 | 5/5 | 0.0184 |
| Residual stones after surgery | 7/57 | 1/5 | 0.511 |
| Stone recurrence | 5/57 | 0/5 | >0.999 |
| Postoperative repeated cholangitis | 11/57 | 2/5 | 0.28 |
| Postoperative jaundice | 11/57 | 3/5 | 0.0712 |
†, Patients for which details of variable were not be available were excluded; ‡, Right or left hepatectomy with or without partial resection of the other part of the liver; ‡†, Precancerous lesions included biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9
Figure 3Immunohistochemical Staining of Biliary Intraepithelial Neoplasia Specimens by γ-H2AX and S100P. Magnification, ×200. (A) Biliary intraepithelial neoplasia. HE staining. (B) Immunohistochemical staining for γ-H2AX. (C) Immunohistochemical staining for S100P